MDxHealth SA (MDXH) vs Exagen Inc. (XGN)

MDxHealth SA and Exagen Inc. are both Diagnostics & Research companies. Exagen Inc. is the larger, with a market value of $233.3M against $55.5M — 4.2× the size. MDxHealth SA grew revenue faster over the last twelve months: 21.5% against 20.8%. Exagen Inc. has the higher net margin (−26.6% vs −32.5%) and the lower return on invested capital (−68.3% vs −23.8%). Across the 17 metrics below, MDxHealth SA leads on 13 and Exagen Inc. on 4.

Valuation

Metric MDXH XGN Diagnostics & Research median
P/E n/m n/m 33.95
P/S 0.26 2.96 4.87
P/B n/m 17.25 3.12
Price to free cash flow n/m n/m 34.02
EV/EBITDA n/m n/m 25.20
EV/Sales 1.00 2.96 5.66
Earnings yield (126.32%) (9.29%) (1.75%)
Free cash flow yield (23.39%) (3.60%) (0.13%)

Profitability

Metric MDXH XGN Diagnostics & Research median
Gross margin 63.23% 58.64% 50.89%
Operating margin (18.04%) (18.58%) (8.57%)
Net margin (32.53%) (26.61%) (6.37%)
Free cash flow margin (5.24%) (10.66%) 0.00%
Return on equity 238.67% (113.82%) (2.92%)
Return on assets (27.38%) (34.19%) (6.71%)
Return on invested capital (23.77%) (68.33%) 0.00%

Growth

Metric MDXH XGN Diagnostics & Research median
Revenue growth (TTM) 21.46% 20.83% 7.69%
EPS growth (last fiscal year) 42.24% (12.05%) —
Revenue growth, 5-year CAGR 42.34% 9.66% 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MDXH XGN Diagnostics & Research median
Debt to equity (3.42) 2.00 0.11
Current ratio 1.15 3.18 2.02
Net debt to EBITDA (10.71) 0.68 0.78

Dividend

Metric MDXH XGN Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio — 0.00 0.00

Size

Metric MDXH XGN Diagnostics & Research median
Market cap 55.53m 233.29m 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack